合富中国王琼芝：以“新质”造“富”医疗服务

Core Viewpoint - 合富中国 is transforming the medical supply chain industry by leveraging AI and digital transformation to enhance operational efficiency and resource allocation in healthcare [1][4]. Group 1: Company Development - 合富中国 was founded in 1997 in Shanghai and has evolved significantly over 28 years, becoming a leader in the medical supply chain sector [2]. - The company became a pioneer in providing refined management services for in vitro diagnostic reagents and consumables in 2008, helping hospitals reduce costs [2]. - In 2022, 合富中国 was listed on the Shanghai Stock Exchange, which has led to increased market competitiveness and brand recognition through joint ventures and acquisitions [3]. Group 2: ACME Empowerment Plan - The ACME empowerment plan, launched in early 2024, consists of four components: AI-assisted clinical diagnosis, an integrated hospital decision analysis platform, a digital platform for surgical education, and a medical integration and interaction platform [4]. - The ACME plan has shown significant results, including partnerships with major hospitals for AI-assisted diagnostic systems and the successful local production of surgical products [5]. Group 3: Future Strategy - The company aims to enhance its research and development in AI, expand market channels, and integrate the supply chain to adapt to tightening hospital budgets due to healthcare cost control policies [7]. - 合富中国 is actively pursuing partnerships and acquisitions to strengthen its position in the medical supply chain, exemplified by a recent collaboration with 晋弘科技 [7][8].